13 results about "Felodipine" patented technology

The invention relates to the field of pharmacy, and discloses a felodipine sustained release tablet and a preparation method thereof.The felodipine sustained release tablet comprises a tablet core and a film coating layer wrapped outside the tablet core, and the tablet core comprises the following components in parts by mass: 3.5-5.0 parts of felodipine nanocrystals; 50 to 65 parts of modified hydroxypropyl methylcellulose; the preparation method comprises the following steps: S1, preparing felodipine nanocrystals: dissolving felodipine in an organic solvent, and carrying out anti-solvent precipitation and high-pressure homogenization treatment, so as to obtain a nanocrystal suspension; drug nanocrystals are embedded between silicate layers through an ultrasonic embedding technology, and burst release is inhibited by combining physical confinement and electrostatic adsorption; the gradient pore skeleton constructs a pore layer-by-layer decreasing structure through fluidized bed multi-temperature zone deposition, the release rate is accurately regulated and controlled, and collapse is avoided; the ionic liquid stabilizer is introduced, and the problems of nanocrystal aggregation and degradation are synchronously solved through hydrogen bond anchoring and an antioxidant function.

The invention relates to an application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and medicinal preparations. The invention provides application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV (human papillomavirus) infection. The dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. According to the scheme, the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV is reported for the first time, and an in-vitro cell experiment is carried out through azelnidipine in the dihydropyridine compound; furthermore, the inhibition effect on the HPV virus is verified through mouse intradermal vaccination virus model drug delivery and mouse vaginal vaccination virus model drug delivery.

A felodipine liposome, and the preparation and use thereof. The felodipine liposome comprises felodipine, a phospholipid and cholesterol, wherein the mass ratio of the felodipine to the phospholipid is 1:8 to 1:20; and the mass ratio of the phospholipid to the cholesterol is 5:1 to 20:1. Furthermore, the felodipine liposome may further contain octadecylamine, wherein the mass ratio of the cholesterol to the octadecylamine is 1:1 to 1:3. The use of the felodipine or felodipine liposome or felodipine liposome lyophilized powder in the preparation of an anti-tumor drug. The tumor is colorectal cancer, liver cancer, ovarian cancer or breast cancer, and in particular, the felodipine or felodipine liposome or felodipine liposome lyophilized powder exhibits the most potent inhibitory effect on colorectal cancer.

The invention belongs to the technical field of medicines, and relates to felodipine liposome as well as preparation and application thereof. The felodipine liposome disclosed by the invention comprises felodipine, phospholipid and cholesterol, wherein the mass ratio of the felodipine to the phospholipid is (1: 8)-(1: 20); the mass ratio of the phospholipid to the cholesterol is (5: 1)-(20: 1); furthermore, the felodipine liposome can also contain octadecylamine, and the mass ratio of the cholesterol to the octadecylamine is (1: 1)-(1: 3). The invention also provides an application of the felodipine or the felodipine liposome or the freeze-dried powder of the felodipine liposome in preparation of antitumor drugs. The tumors are colorectal cancer, liver cancer, ovarian cancer and breast cancer, and especially have the strongest inhibition effect on the colorectal cancer.

The invention discloses a high performance liquid chromatography detection method for an intermediate 2 in felodipine tablets, and belongs to the technical field of analytical chemistry. The method comprises the following steps: preparing a blank auxiliary material solution, a system applicability solution, a test solution and a reference solution; setting liquid chromatography detection conditions: adopting a chromatographic column taking octadecylsilane chemically bonded silica as a filling agent; and finally, respectively taking the blank auxiliary material solution, the system applicability solution, the test solution and the reference substance solution, injecting into a liquid chromatograph, and recording chromatograms. The detection retention capacity is high, matrix interference is small, the intermediate 2 is strongly retained in the chromatographic system, and a solvent peak and an auxiliary material peak do not interfere with detection of the intermediate 2; the method has the advantages of high specificity and high sensitivity, the separation degree of the intermediate 2 with felodipine and other impurities in the chromatographic system is good, the response is high, the felodipine and other impurities can be accurately detected at a low concentration level, and a technical guarantee is provided for ensuring the quality of felodipine tablets and the subsequent drug safety.

An osmotic pump controlled-release tablet of an insoluble drug includes a tablet core, a semi-permeable membrane coating and a drug-release hole, wherein the tablet core includes a solid dispersion of the insoluble drug and a penetration enhancer, the solid dispersion of the insoluble drug includes the insoluble drug and a carrier, the insoluble drug is selected from nicardipine, nifedipine and felodipine and pharmaceutically acceptable salts thereof, and the carrier is selected from organic acids. Compared with other tablets, the drug solubility of the osmotic pump controlled-release tablet of the insoluble drug is improved, a large amount of penetration enhancers or other excipients do not need to be used in the tablet core, the drug-loading capacity is improved, and the tablet core is not too large; the degree of release in vivo is improved.

The present invention provides cilnidipine, nilvadipine, isradipine, felodipine, verapamil, nimodipine or nifedipine, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment or prophylaxis of Attention Deficit / Hyperactivity Disorder (ADHD). The invention also provides kits and methods for the treatment or prophylaxis of ADHD.

The application relates to application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and pharmaceutical preparations. The application provides application of the dihydropyridine compound or the salt thereof in preparation of the medicine for preventing and / or treating HPV infection, wherein the dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. The application scheme first reports the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV, and in-vitro cell experiments are carried out through azelnidipine in the dihydropyridine compound, and further, the inhibiting effect of the dihydropyridine compound on HPV virus is verified through medicine administration of a mouse intradermal virus inoculation model and medicine administration of a mouse vaginal virus inoculation model.

The present application relates to a kind of poorly soluble drug osmotic pump controlled-release tablets and its preparation method, the osmotic pump controlled-release tablets include tablet core, semi-permeable membrane coating and release hole, the tablet core includes solid dispersion of poorly soluble drug and penetration agent, the solid dispersion of poorly soluble drug includes poorly soluble drug and carrier, the poorly soluble drug is selected from nicardipine, nifedipine, felodipine and their pharmaceutically acceptable salt, the carrier is selected from organic acid substance.Compared with prior art, the poorly soluble drug osmotic pump controlled-release tablets of the present application greatly improves the drug solubility, without using a large amount of penetration agent or other excipients in tablet core, drug loading is increased, and tablet core will not be too large;In vivo release greatly improves;Preparation process is simple, equipment requirement and cost are low, and easy to industrialization.

The utility model discloses a non - furosemide reation kettle of protection structure, specifically at related to pharmaceutical preparation technical field, including the reation kettle, the reation kettle top is equipped with the sealing cover, the sealing cover top is fixedly connected with the feed pipe, the reation kettle top is provided with the heat exchange protection mechanism, the heat exchange protection mechanism includes the fixed box, the fixed box is fixed in the sealing cover top, the sealing cover top is fixedly installed with the heat exchange box in the fixed box one side, the utility model discloses through circulating pump drive coolant circulation, realizes the efficient heat exchange to the reation kettle, and the air release valve opens and makes the high -temperature gas through the air release pipe and enters the heat exchange box, and its heat is absorbed by coolant, reduces gas temperature and maintains the pressure stability in the reation kettle, ensures that non - furosemide production reaction is carried out under the suitable temperature and pressure condition, improves product quality and production efficiency, avoids the scald, fire and other safety problems that high -temperature gas direct emission brings, provides the protection effect.

The present application provides a kind of felodipine osmotic pump controlled-release tablets and preparation method thereof, the osmotic pump controlled-release tablet is composed of osmotic pump controlled-release tablet core and water-insoluble coating layer (single side laser punching), the weight percentage of the felodipine osmotic pump controlled-release tablet contains immediate-release coating layer, controlled-release coating layer, propelling coating layer, water-insoluble coating layer is (5~20) :(5~30) :(10~50) :(5~30).The present application also provides a kind of preparation method of felodipine osmotic pump controlled-release tablet and its application in treating hypertension.The formulation of the felodipine osmotic pump controlled-release tablet of the present application is reasonable, and production process is simple and easy to control;By replacing traditional controlled-release tablet polyethylene oxide with different povidone, the controllability of felodipine osmotic pump controlled-release tablet preparation is significantly improved, and the difficulty of cleaning in production is reduced.

The present application relates to the technical field of pharmaceutical preparation, and particularly discloses a felodipine enalapril tablet and a preparation method thereof. The felodipine enalapril tablet takes hydrochloric acid felodipine and maleic acid enalapril as active ingredients, and the auxiliary materials include lactose monohydrate, microcrystalline cellulose, crosslinked polyvinylpyrrolidone, sodium bicarbonate, povidone and magnesium stearate. The tablet is prepared through the processes of separate granulation, mixing, tabletting and coating. The felodipine enalapril tablet prepared by the present application has similar dissolution curve to the reference preparation, uniform content and good stability.

The invention provides a pharmaceutical composition. The pharmaceutical composition comprises felodipine, atenolol, folic acid substances and pharmaceutically acceptable auxiliary materials. The composition provided by the invention can also comprise telmisartan. The pharmaceutical composition provided by the invention can be used for preparing medicines for treating coronary heart disease, and has the effects of improving myocardial ischemia and reducing the occurrence risk of cardiovascular events.